Geron lands potential $900M blood cancer drug deal with J&J
Geron Corp. will hand over its experimental blood cancer drug imetelstat to Johnson & Johnson's Janssen Biotech Inc. unit for $35 million upfront, the Menlo Park company said Thursday.
The deal ultimately could be worth $900 million if certain development, regulatory and commercial milestones are hit over several years.
Janssen will lead mid-stage studies of the drug in myelofibrosis, myelodysplastic syndrome and acute myelogenous leukemia.
Development costs for the two studies in myelofibrosis,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Biotechnology | Cancer | Cancer & Oncology | Health | Health Management | Leukemia | Men | Myelodysplastic Syndrome | Study